The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis

Archives of Dermatology

Volumn 134, Issue 1, 1998, Pages 57-60

  Krueger, Gerald G ^a   Drake, Lynn A ^b   Elias, Peter M ^e   Lowe, Nicholas J ^f   Guzzo, Cynthia ^c   Weinstein, Gerald D ^d   Lew Kaya, Deborah A ^g   Lue, John C ^g   Sefton, John ^g   Chandraratna, Roshantha A S ^g  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Skin Res Foundation of California   (United States)

^g ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; RETINOID; TAZAROTENE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; ERYTHEMA; FOLLOW-UP STUDIES; GELS; HUMANS; NICOTINIC ACIDS; PRURITUS; PSORIASIS; RETINOIDS; SAFETY; TREATMENT OUTCOME; VEHICLES;

EID: 0031933439     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.1.57     Document Type: Article

References (6)

1. Lowe NJ. Systemic retinoid therapy. In: Weinstein GD, Gottlieb AB, eds. Therapy of Moderate-to-Severe Psoriasis. Portland, Ore: National Psoriasis Foundation; 1993;94-105.
2. Phillips TJ, Dover JS. Recent advances in dermatology. N Engl J Med. 1992;326:167-178.
3. Nesher G, Zuckner J. Rheumatologic complications of vitamin A and retinoids. Semin Arthritis Rheum. 1995;24:291-296.
4. Mitchell AA. Oral retinoids: what should the prescriber know about their teratogenic hazards among women of child-bearing potential? Drug Saf. 1992;7:79-85.
5. Sturkenboom MCJM, DeJong-van den Berg LTW, van Voorst-Vader PC, Cornel MC, Stricker BHCH, Wesseling H. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. Br J Clin Pharm. 1994;38:229-235.
6. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, Sefton J, Duvic M. Response of psoriasis to a new topical retinoid, tazarotene. J Am Acad Dermatol. 1994;30:581-590.